DaVita Reaches New 52-Week High (DVA)

NEW YORK ( TheStreet) -- DaVita (NYSE: DVA) hit a new 52-week high Friday as it is currently trading at $89.90, above its previous 52-week high of $89.79 with 19,232 shares traded as of 9:45 a.m. ET. Average volume has been 719,600 shares over the past 30 days.

DaVita has a market cap of $7.56 billion and is part of the health care sector and health services industry. Shares are up 17.8% year to date as of the close of trading on Thursday.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. The company has a P/E ratio of 17.7, below the average health services industry P/E ratio of 19.4 and equal to the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates DaVita as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, increase in stock price during the past year and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated. You can view the full DaVita Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Buy It Like Buffett -- or Better

Buy It Like Buffett -- or Better